EPZM - エピザイム (Epizyme Inc.)

EPZMのニュース

   Epizyme gains as peer Constellation attracts sizable premium from MorphoSys  2021/06/02 16:48:57 Seeking Alpha
   The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping  2021/03/24 12:59:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS ) ( announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX ) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) Soliton, Inc. (NASDAQ: SOLY ) Radius Health, Inc. (NASDAQ: RDUS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) Connect Biopharma Holdings Limited (NASDAQ: CNTB ) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) (IPOed Friday) Frequency Therapeutics, Inc. (NASDAQ: FREQ ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) Ibere Pharmaceuticals (NYSE: IBER-UN) Instil Bio, Inc. (NASDAQ: TIL ) (IPOed Friday) Odonate Therapeutics, Inc. (NASDAQ: ODT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Soleno Therapeutics, Inc. (NASDAQ: SLNO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus LabCorp to Review Structure And Capital Allocation Strategy Laboratory Corporation of America Holdings (NYSE: LH ) said its board is undertaking a review of its structure and capital allocation strategy to ensure the company is best positioned to unlock shareholder value while it continues to support patients and customers around the world.
   The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study  2021/03/05 13:15:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC ) Five Prime Therapeutics, Inc. ( NASDAQ: FPRX) - announced a deal to be bought by Amgen Inc. (NASDAQ: AMGN ) for $1.9 billion Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 4) AbCellera Biologics Inc. (NASDAQ: ABCL ) Acutus Medical, Inc. (NASDAQ: AFIB ) ADC Therapeutics SA (NYSE: ADCT ) Aptose Biosciences Inc. (NASDAQ: APTO ) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Athenex, Inc. (NASDAQ: ATNX ) Biophytis SA (NASDAQ: BPTS ) Bioventus Inc. (NASDAQ: BVS ) Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) BriaCell Therapeutics Corp. (NASDAQ: BCTX ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) Dyne Therapeutics, Inc. (NASDAQ: DYN ) (reacted to fourth-quarter results) Epizyme, Inc. (NASDAQ: EPZM ) Freeline Therapeutics Holdings plc (NASDAQ: FRLN ) Galecto, Inc. (NASDAQ: GLTO ) Inhibikase Therapeutics, Inc.
   Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call  2021/03/02 17:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call today outlining the Company’s strategic vision and focus on oncology treatment with the Company’s epigenetic pipeline. A link to the presentation and slideshow can be found here. “The recent accelerated approvals of TAZVERIK in Epithelioid Sarcoma and Relapsed / Refractory Follicular Lymphoma are, of c
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.
   Barclays Stick to Their Buy Rating for Epizyme By Investing.com  2021/02/25 01:15:23 Investing.com
Barclays Stick to Their Buy Rating for Epizyme
   Global Atypical Teratoid Rhabdoid Tumors (ATRT) Pipeline Insights Report 2020 Featuring Takeda Oncology, Epizyme, Vyriad, Novartis, DNAtrix, Pfizer, Oncoceutics & Istari Oncology - ResearchAndMarkets.com  2021/02/05 12:49:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight - 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2020," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therape
   Epizyme to Participate in Jefferies Virtual London Healthcare Conference  2020/11/11 21:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme to Participate in Jefferies Virtual London Healthcare Conference
   Epizyme Wall street estimates Earnings report Stock market Insights & financial analysis  2020/11/06 15:20:00 Stock Market Daily
Epizyme announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Epizyme Reports Business Progress and Third Quarter 2020 Financial Results  2020/11/06 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business and portfolio updates and reported third quarter 2020 financial results. “2020 has been a year of big milestones for Epizyme, and we are executing our TAZVERIK® launches well, given the unprecedented challenges presented by the COVID-19 pandemic on FL patients’ access to their physicians and on ac
   Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives  2020/11/06 11:05:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the company has entered into an amended and restated agreement with funds managed by Pharmakon Advisors, LP, an affiliate of Royalty Pharma, to expand its loan facility and plans to draw down $150 million. Epizyme and Pharmakon Advisors originally executed their agreement in November 2019, in conjunc

calendar